$35M QVAR Inhaler Antitrust Settlement — Claim by July 2026
Who Is Eligible?
You may be eligible to file a claim if you:
- You purchased a QVAR inhaler (beclomethasone dipropionate) at any point during the eligible claim period
- Your purchase was made in the United States
- You paid for QVAR out of pocket, through a co-pay, or via a health insurance plan
- You are an individual consumer or third-party payer (such as an insurer or benefits plan) who purchased QVAR during the covered timeframe
- Specific eligibility dates are pending — check the official settlement website or use Class Action Buddy for the latest details
How Much Can You Get?
The total settlement fund is $35 million, which will be distributed among eligible claimants after legal fees and administrative costs are deducted. The exact amount each person receives will depend on how many valid claims are submitted and the quantity of QVAR purchased during the covered period. Individual payout amounts have not yet been publicly detailed, but consumers who purchased QVAR multiple times or over an extended period may receive a higher share. Keep in mind that settlements like this one often result in smaller individual checks — but filing takes only minutes and costs you nothing to try.How to File Your Claim
Filing your claim is quick and easy:
- Confirm you purchased a QVAR inhaler during the eligible period
- Gather any documentation you may have, such as pharmacy receipts, insurance explanation of benefits (EOB) statements, or prescription records — proof requirements are still being confirmed
- Visit the official settlement claims website (details pending) or use Class Action Buddy to be notified when the claim form goes live
- Complete the claim form with your personal information and purchase details
- Submit your claim before the July 2026 deadline
- Download the Class Action Buddy app to track your claim status, get deadline reminders, and discover other settlements you may qualify for
💡 Easier way: File with Class Action Buddy
Skip the paperwork. Our app auto-fills your claim form with your saved profile and submits it electronically in under 2 minutes.
Download for iPhone Download for AndroidFrequently Asked Questions
How do I file a claim for the $35M QVAR Inhaler Antitrust Settlement — Claim by July 2026?
You have two options: (1) Use the free Class Action Buddy mobile app — set up your profile once and the app auto-fills the PDF claim form, captures your signature, and submits the claim by mail on your behalf. (2) File directly with the settlement administrator using the official claim form linked on this page.
Who is eligible for the QVAR inhaler antitrust settlement?
Anyone who purchased a QVAR inhaler in the United States during the covered claim period may be eligible. This includes people who paid out of pocket, through a co-pay, or via health insurance. Full eligibility details and exact dates are still being confirmed — check back for updates or download Class Action Buddy to stay informed.
Do I need proof of purchase to file a QVAR settlement claim?
Proof requirements have not yet been officially confirmed for this settlement. It's a good idea to gather any pharmacy receipts, insurance statements, or prescription records you may have, just in case. Class Action Buddy will update users as soon as official claim requirements are published.
What was Teva accused of doing with the QVAR inhaler?
The lawsuit alleged that Teva Pharmaceuticals engaged in anticompetitive behavior that delayed the availability of lower-cost generic versions of QVAR, forcing consumers and insurers to pay inflated prices for the brand-name inhaler longer than they should have. Teva has agreed to the $35 million settlement without admitting wrongdoing.
Ready to File Your Claim?
We're adding new settlements regularly. Download the app to get notified when this one is available.
Download Class Action Buddy →Get Notified About New Settlements
We find new class action settlements every week. Get alerts so you never miss free money.
No spam. Unsubscribe anytime. We respect your privacy.